{"raw_mentions": "There are no sentences that contain all four required components: a specific molecule name, ID or other identifier, a bioactivity metric (IC50, Ki, Kd, EC50), a specific numeric value for that metric, and a unit for that value. The text appears to be a collection of chemical compound descriptions, synthesis methods, and spectroscopic data, but it does not include bioactivity metrics or their corresponding values and units."}
{"raw_mentions": "There are no sentences that contain all four required components: a specific molecule name, ID or other identifier, a bioactivity metric (IC50, Ki, Kd, EC50 and their variations), a specific numeric value for that metric, and a unit for that value. The text appears to be a collection of chemical synthesis procedures and spectral data, but does not include bioactivity data."}
{"raw_mentions": "There are no sentences that contain all four required components: a specific molecule name, ID or other identifier, a bioactivity metric (IC50, Ki, Kd, EC50), a specific numeric value for that metric, and a unit for that value. The text appears to be a description of chemical synthesis and characterization, but it does not include any bioactivity data."}
{"raw_mentions": "Unfortunately, there are no sentences that contain all four required components: a specific molecule name, ID or other identifier, a bioactivity metric (IC50, Ki, Kd, EC50), a specific numeric value for that metric, and a unit for that value.\n\nHowever, I can provide some sentences that contain some of the required components, but not all:\n\n* Compound IC50 curves were analyzed using GraphPad Prism 7.0 (GraphPad company, usa) and Ki affinity values were determined from the obtained IC50 values using the method of Cheng and prusofff.\n* The data for the dose response curve were calculated as% inhibition, 100% inhibition being defined by the agonist-free control wells (+CD3/28-NECA)\n* The adenosine receptor antagonist XAC (CA 200645, FRET acceptor) was used to investigate the ability of unlabeled test compounds to bind to adenosine A1, A2a, A2b and A3 receptors.\n\nPlease note that these sentences do not meet the requirements, but they contain some relevant information. If you would like me to extract more information or clarify any of these points, please let me know."}
{"final_json": [{"molecule_name": null, "protein_target_name": null, "binding_metric": "IC50, Ki", "value": null, "unit": null}, {"molecule_name": null, "protein_target_name": null, "binding_metric": null, "value": null, "unit": "%"}, {"molecule_name": "XAC (CA 200645)", "protein_target_name": "adenosine A1, A2a, A2b and A3 receptors", "binding_metric": null, "value": null, "unit": null}]}
{"raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe adenosine receptor agonist NECA was then added at a final concentration of 1 \u03bcm, resulting in increased CREB phosphorylation.\nThe cells were incubated with the phosphodiesterase inhibitor rolipram (final concentration of 20 \u03bcm) to enhance the subsequent pCREB response.\n\n\nNote that there are only two sentences that contain all four required components: a specific molecule name (NECA, rolipram), a bioactivity metric (concentration), a specific numeric value (1 \u03bcm, 20 \u03bcm), and a unit (\u03bcm). The rest of the text does not provide specific bioactivity metrics with numeric values and units."}
{"final_json": [{"molecule_name": "NECA", "protein_target_name": null, "binding_metric": "concentration", "value": "1", "unit": "\u03bcm"}, {"molecule_name": "rolipram", "protein_target_name": null, "binding_metric": "concentration", "value": "20", "unit": "\u03bcm"}]}
